Form 8-K - Current report:
SEC Accession No. 0001193125-26-344594
Filing Date
2026-08-11
Accepted
2026-08-11 16:05:48
Documents
12
Period of Report
2026-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d161230d8k.htm   iXBRL 8-K 26290
2 EX-99.1 d161230dex991.htm EX-99.1 88101
  Complete submission text file 0001193125-26-344594.txt   242304

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20260811.xsd EX-101.SCH 3172
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20260811_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20260811_pre.xml EX-101.PRE 11256
15 EXTRACTED XBRL INSTANCE DOCUMENT d161230d8k_htm.xml XML 3637
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 261263145
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)